Spain-based Laboratorios Almirall has entered into a definitive agreement to acquire a portfolio of eight products from Shire for $213m (€151m)
Almirall Sofotec is the Research and Development (R & D) Centre of Excellence for Inhalation Technology of Almirall, a consolidated international pharmaceutical company in continuous international expansion. Almirall is focussing on international expansion, with the Shire acquisition a step onto English soil. The company’s portfolio acquired consists of two dermatology products: Solaraze (diclofenac sodium) and Vaniqa (eflornithine).
The six other products include: Lodine (etodolac), for rheumatoid arthritis; Colazide (balsalazide disodium), for ulcerative colitis; Cebutid (flurbiprofen), for rheumatoid arthritis; meptid (meptazinol), for pain; Robaxin (methocarbamol), a muscle relaxant; and Mintec (peppermint oil BP), for irritable bowel syndrome. Also with this move, Almirall expands its range of dermatological products and reinforces its portfolio in the area of pain, gastrointestinal and inflammatory diseases.
Shire plc (Shire) is a specialty pharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. Shire focuses its business on attention deficit and hyperactivity disorder, human genetic therapies, gastrointestinal and renal diseases. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.